Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill Cosp, Joan Caroline Bradbury, Michael Clarke, Rory Collins, Susan Ruth Davis, Antonella Delmestri, John Forbes, Peiman Haddad, Ming-Feng Hou, Moshe Inbar, Hussein KhaledJoanna Kielanowska, Wing-Hong Kwan, Beela Mathew, Indraneel Mittra, Bettina Muller, Antonio Nicolucci, Octavio Peralta, Fany Pernas, Lubos Petruzelka, Tadeusz Pienkowski, Ramachandran Radhika, Balakrishnan Rajan, Maryna Rubach, Sera Tort, Gerard Urrutia, Miriam Valentini, Yaochen Wang, Richard Peto

Research output: Contribution to journalArticleResearchpeer-review

992 Citations (Scopus)

Abstract

For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. The study aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years.
Original languageEnglish
Pages (from-to)805 - 816
Number of pages12
JournalThe Lancet
Volume381
Issue number9869
DOIs
Publication statusPublished - 2013

Cite this

Davies, Christina ; Pan, Hongchao ; Godwin, Jon ; Gray, Richard ; Arriagada, Rodrigo ; Raina, Vinod ; Abraham, Mirta ; Alencar, Victor Hugo Medeiros ; Badran, Atef ; Bonfill Cosp, Xavier ; Bradbury, Joan Caroline ; Clarke, Michael ; Collins, Rory ; Davis, Susan Ruth ; Delmestri, Antonella ; Forbes, John ; Haddad, Peiman ; Hou, Ming-Feng ; Inbar, Moshe ; Khaled, Hussein ; Kielanowska, Joanna ; Kwan, Wing-Hong ; Mathew, Beela ; Mittra, Indraneel ; Muller, Bettina ; Nicolucci, Antonio ; Peralta, Octavio ; Pernas, Fany ; Petruzelka, Lubos ; Pienkowski, Tadeusz ; Radhika, Ramachandran ; Rajan, Balakrishnan ; Rubach, Maryna ; Tort, Sera ; Urrutia, Gerard ; Valentini, Miriam ; Wang, Yaochen ; Peto, Richard. / Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. In: The Lancet. 2013 ; Vol. 381, No. 9869. pp. 805 - 816.
@article{ffb361b106ad4d8480eb39d9476b67ae,
title = "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial",
abstract = "For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. The study aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years.",
author = "Christina Davies and Hongchao Pan and Jon Godwin and Richard Gray and Rodrigo Arriagada and Vinod Raina and Mirta Abraham and Alencar, {Victor Hugo Medeiros} and Atef Badran and {Bonfill Cosp}, Xavier and Bradbury, {Joan Caroline} and Michael Clarke and Rory Collins and Davis, {Susan Ruth} and Antonella Delmestri and John Forbes and Peiman Haddad and Ming-Feng Hou and Moshe Inbar and Hussein Khaled and Joanna Kielanowska and Wing-Hong Kwan and Beela Mathew and Indraneel Mittra and Bettina Muller and Antonio Nicolucci and Octavio Peralta and Fany Pernas and Lubos Petruzelka and Tadeusz Pienkowski and Ramachandran Radhika and Balakrishnan Rajan and Maryna Rubach and Sera Tort and Gerard Urrutia and Miriam Valentini and Yaochen Wang and Richard Peto",
year = "2013",
doi = "10.1016/S0140-6736(12)61963-1",
language = "English",
volume = "381",
pages = "805 -- 816",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "9869",

}

Davies, C, Pan, H, Godwin, J, Gray, R, Arriagada, R, Raina, V, Abraham, M, Alencar, VHM, Badran, A, Bonfill Cosp, X, Bradbury, JC, Clarke, M, Collins, R, Davis, SR, Delmestri, A, Forbes, J, Haddad, P, Hou, M-F, Inbar, M, Khaled, H, Kielanowska, J, Kwan, W-H, Mathew, B, Mittra, I, Muller, B, Nicolucci, A, Peralta, O, Pernas, F, Petruzelka, L, Pienkowski, T, Radhika, R, Rajan, B, Rubach, M, Tort, S, Urrutia, G, Valentini, M, Wang, Y & Peto, R 2013, 'Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial', The Lancet, vol. 381, no. 9869, pp. 805 - 816. https://doi.org/10.1016/S0140-6736(12)61963-1

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. / Davies, Christina; Pan, Hongchao; Godwin, Jon; Gray, Richard; Arriagada, Rodrigo; Raina, Vinod; Abraham, Mirta; Alencar, Victor Hugo Medeiros; Badran, Atef; Bonfill Cosp, Xavier; Bradbury, Joan Caroline; Clarke, Michael; Collins, Rory; Davis, Susan Ruth; Delmestri, Antonella; Forbes, John; Haddad, Peiman; Hou, Ming-Feng; Inbar, Moshe; Khaled, Hussein; Kielanowska, Joanna; Kwan, Wing-Hong; Mathew, Beela; Mittra, Indraneel; Muller, Bettina; Nicolucci, Antonio; Peralta, Octavio; Pernas, Fany; Petruzelka, Lubos; Pienkowski, Tadeusz; Radhika, Ramachandran; Rajan, Balakrishnan; Rubach, Maryna; Tort, Sera; Urrutia, Gerard; Valentini, Miriam; Wang, Yaochen; Peto, Richard.

In: The Lancet, Vol. 381, No. 9869, 2013, p. 805 - 816.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

AU - Davies, Christina

AU - Pan, Hongchao

AU - Godwin, Jon

AU - Gray, Richard

AU - Arriagada, Rodrigo

AU - Raina, Vinod

AU - Abraham, Mirta

AU - Alencar, Victor Hugo Medeiros

AU - Badran, Atef

AU - Bonfill Cosp, Xavier

AU - Bradbury, Joan Caroline

AU - Clarke, Michael

AU - Collins, Rory

AU - Davis, Susan Ruth

AU - Delmestri, Antonella

AU - Forbes, John

AU - Haddad, Peiman

AU - Hou, Ming-Feng

AU - Inbar, Moshe

AU - Khaled, Hussein

AU - Kielanowska, Joanna

AU - Kwan, Wing-Hong

AU - Mathew, Beela

AU - Mittra, Indraneel

AU - Muller, Bettina

AU - Nicolucci, Antonio

AU - Peralta, Octavio

AU - Pernas, Fany

AU - Petruzelka, Lubos

AU - Pienkowski, Tadeusz

AU - Radhika, Ramachandran

AU - Rajan, Balakrishnan

AU - Rubach, Maryna

AU - Tort, Sera

AU - Urrutia, Gerard

AU - Valentini, Miriam

AU - Wang, Yaochen

AU - Peto, Richard

PY - 2013

Y1 - 2013

N2 - For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. The study aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years.

AB - For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. The study aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years.

UR - http://goo.gl/fcF2QL

U2 - 10.1016/S0140-6736(12)61963-1

DO - 10.1016/S0140-6736(12)61963-1

M3 - Article

VL - 381

SP - 805

EP - 816

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9869

ER -